Vimarsana
Biggest News Aggregation in the World

Page 14 - Neurological Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neurological Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neurological Sciences Today - Breaking & Trending Today

Report of the president: Academic Council Professoriate appointments - Vimarsana News

Report of the president: Academic Council Professoriate appointments

The following Academic Council Professoriate appointments, promotions, and reappointments for the periods indicated were reviewed by the Advisory Board of the Academic Council on Sept. 20, Oct. 4, Oct. 11, Oct. 18, and Nov. 1, 2022, and were approved by the President. Please note that while all appointments below have been approved by the president, some candidates may not have accepted offers.

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders - Vimarsana News

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders

Zynerba Pharmaceuticals Announces Publication of Data from Phase 3 CONNECT-FX Study of Zygel™ in the Journal of Neurodevelopmental Disorders - read this article along with other careers information, tips and advice on BioSpace

Is It Long COVID, or Dementia, or Both? - Vimarsana News

Is It Long COVID, or Dementia, or Both?

COVID-19 makes some older patients confused, and their brains don't regain their former clarity.

Recommending Exercise for Migraine: Just Do It - Vimarsana News

Recommending Exercise for Migraine: Just Do It

Strength training is the most effective form of exercise for reducing migraine, with high-intensity aerobics coming in second, but both beat top-line migraine meds topiramate and amitriptyline, new research suggests.

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential - Vimarsana News

EQS-News: Immunic, Inc.: Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential

Issuer: Immunic, Inc. / Key word(s): Study results/Conference Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting